Zydus Cadila ZyCoV-D Vaccine: According to the central government, the Zydus Cadila corona vaccine may be available from the first week of October. At the same time, a decision will be taken after consulting the National Technical Advisory Group on Immunization, ie the NTAGI, on the advisability of administering it to children between 12 and 17 years old. Zydus Cadila’s Corona vaccine recently received emergency use authorization from the Drug Controller General of India. The special thing is that it is the world’s first DNA vaccine against Corona. At the same time, it is the first Indian vaccine that can be given to people over 12 years old.
Today, the Department of Health made it clear that Zydus Cadila’s ZyCoV-D DNA-based corona vaccine will be available from the first week of October. Zydus Cadila is India’s sixth corona vaccine to be granted emergency use authorization. This vaccine can be given to children over 12 years old. However, from when the children will be given, it has not yet been decided. According to the Union Health Secretary, the NTAGI, that is, the National Immunization Technical Advisory Group, will make a decision on this and advise the government, after which a decision will be made.
Union Health Secretary Rajesh Bhushan said: ‘Should priority be given to all children or whether children with co-morbidities should be vaccinated as a priority, as recommended by the Standing Committee on COVID , NTAGI. Once the recommendation was made, which has not happened so far. Once NTAGI recommends on this subject, the government makes a decision on that recommendation. “
At the same time, talks between the government and the company are also underway regarding the price of the vaccine. No decision has yet been made on its price. Rajesh Bhushan said, “The company will be able to deliver this vaccine from the first week of October. This is why we are in talks with them and we will share with you as soon as we have clarified the terms and conditions of purchase. It will be available after the third week of September.
Let us tell you that this is a native vaccine and its clinical trial was done in India itself. It is a DNA-based triple dose vaccine. There are three doses of this vaccine, which will be given 4 to 4 weeks apart. Its efficiency is 66.6%. Injection is not used in this case, but this vaccine is needle-free. It can be administered by jet injector. Pharmajet, a needleless applicator, guarantees painless intradermal vaccine administration.
This vaccine has been tested in people over 12 years old, i.e. the vaccine will be available for children over 12 years old. The company says that by this year, around 40 million doses of the vaccine will be ready.
So far, 6 corona vaccines have been authorized in India. Vaccines from Astragenica and Serum Institute of India, Covaxin from Bharat Biotech, Sputnik, Moderna and Johnson & Johnson in Russia, have so far received emergency use authorization in India from the Drug Controller General of India.
